GLP-1

17 · 20 / page

Ask MedXY AI

Latest news

Tag

Diabetes & Endocrinologygastric emptyingGLP-1

An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide

By MedXY|Jun 9, 2026

A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

Clinical UpdatesBeta-cell Protection

GLP-1

Latest news

An Obesity Subphenotype With Low Endogenous GLP-1 Production Shows Markedly Greater Weight Loss With Tirzepatide

Synergistic Protection of Pancreatic Beta Cells: GLP1-E2 and Low-Dose Anti-CD3 Combination Therapy in Autoimmune Diabetes

Managing Obesity as a Chronic Disease: The 2026 WHO Guidelines on GLP-1 Therapies

Frontiers in Cardiometabolic Medicine: From Oral GLP-1 Small Molecules to RNAi Therapeutics

Dietary Phytomix Dibifree Reshapes T2D Management by Modulating the Gut-Pancreas-Adipose-Immune Axis

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

HEC88473 Dual GLP-1/FGF21 Agonist: Advancing Treatment for MASLD and T2DM with Promising Safety and Efficacy

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet

What’s New in Diabetes Care: Key Changes from the ADA 2024 Standards of Care

What’s New in Diabetes Care 2024: Key Recommendations from the ADA Standards of Care

ADA Standards of Care 2024: A Clinician-Friendly Guide to the New Cardiorenal‑Metabolic Era in Diabetes Care

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

GLP-1 Receptor Agonists Linked to Early Risk of Optic Nerve Damage: A Case-Control Study Analysis

The Rise of Ozempic and Wegovy: Revolutionizing Weight Loss, But At What Cost?

Ozempic and the Weight Loss Revolution: Miracle Drug or Medical Hype?

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution